A Big Bounce for Cypress Bioscience

Shares soared Wednesday after a neurological drug the company is developing with Forest Labs showed positive results in a clincal trial

Shares in Forest Laboratories (FRX) and Cypress Bioscience (CYPB) climbed May 23 after a neurological drug they are co-developing, Milnacipran, showed positive results in a late-stage clinical trial.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.